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Clinical cardiac transplantation was successfully introduced 26 
years ago, and from an initial experimental status, it has moved 
forward to become an accepted and well-established treatment 
modality for end-stage cardiac disease. The first cardiac trans-
plant operation in Hawaii was performed in March 1987; the 
patient lived for 1 year. A total of 20 heart transplant operations 
have been performed in 19 patients at St. Francis Medical 
Center in Honolulu. There has been only one hospital death, and 
our current one-year survival is 77%, which is similar to national 
statistics. Our longest survivor is now more than 6 years following 
transplantation. The incidence of rejection episodes and infec-
tious complications is comparable to other studies. 
Introduction 
Following successful animal experiments in the late 1950s, 
cardiac transplantation was applied clinically for the first time in 
1967. This event led to an unwarranted rush of transplant 
operations worldwide with resulting poor outcomes. It was 
through the meticulous efforts of the Stanford group with 
steadily improving results in the 1970s that transplantation of 
the heart regained prominence as a valuable procedure in the 
treatment of end-stage cardiac disease. With the introduction of 
cyclosporine as part of the immunosuppressive regimen in 1980, 
a new higher level of success was achieved that produced the 
appearance of many new transplant programs. The surgical 
techniques and immunosuppression protocols have become 
standardized with expected good results. This report reviews the 
experience with heart transplantation in Hawaii since its incep-
tion in 1987. 
Patients and methods 
After months of preparation, the first cardiac transplant 
operation in Hawaii was performed in March 19871• Since that 
time, a total of20 operations have been performed in 19 patients. 
The selection of patients was based on standard criteria: All were 
in advanced cardiac failure and had no other alternative treat-
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ment. There were 17 men and 2 women who were aged 23 to 60 
years old (mean 40). Seventy-four percent of these patients (14/ 
19) had idiopathic dilated cardiomyopathy. Five patients had 
undergone previous cardiac surgery; one patient had 3 previous 
coronary bypass operations and the placement of an AICD. For 
patients who were discharged from the hospital, the length of 
stay varied between 14 and 7 4 days, with an average of24 days. 
The operations were performed between March 1987 and May 
1993, and the follow up was completed in December 1993. A 
profile of the recipient patients is seen in Table 1. 
Our immunosuppression regimen has been modeled after the 
Stanford University protocol and consisted of triple drug oral 
therapy ( cyclosporine, azathioprine and prednisone) plus induc-
tion with the monoclonal antibody OKT3 for 14 days. All 
patients had routine surveillance cardiac biopsies weekly after 
transplantation for the first 6 weeks, biweekly for 2 months, and 
monthly until6 months following the operation. Thereafter, they 
were biopsied every 3 months for life. Once a year, full cardiac 
catheterization and coronary angiography were obtained. 
Rejection was diagnosed in asymptomatic patients on routine 
biopsy using standard criteria and on symptomatic patients by 
clinical diagnosis plus echocardiogram and confirmed by urgent 
biopsy. Treatment of moderate or severe rejection consisted of 
3 consecutive daily doses of 1 gram of methyl-prednisolone. If 
this failed to clear the episode, a second course of methyl-
prednisolone or a repeat course of OKT3 was given. In the case 
of humoral rejection, characterized by the absence of cellular 
infiltrates and severe cardiac failure, plasmapheresis or 
immunoadsorption columns (ProSorba®) were used. This con-
sisted of daily treatments for 3 days, followed by 3 more 
treatments every other day. In patients who rejected several 
months after transplantation, the episode was treated with high 
dose oral steroids (prednisone 50 mg twice a day for 3 days) with 
tapering over 2 weeks. 
Infection surveillance was very strict. All patients (recipients 
and donors) were screened for CMV IgM and IgG, hepatitis, 
toxoplasmosis and HIV. After transplantation, routine cultures 
of sputum and urine were obtained twice a week. Weekly 
specimens of urine, throat secretions, and blood were obtained 
for CMV cultures. Appropriate cultures were repeated when 
clinically indicated. 
Donor management was directed by the transplant surgeons. 
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Hemodynamic stability was emphasized with particular interest 
in maintaining adequate intravascular volume, minimal 
inoptropic support with no more than 5 meg/Kg/min of dopam-
ine and acceptable oxygenation. 
Brain death in 14 of the 20 donors was caused by head trauma; 
5 had spontaneous intracranial hemorrhage, and 1 had a malig-
nant brain tumor (Table 2). Donor age varied from 14 to 50 years 
old with a mean of 28. There were 17 men and 3 women; 
adequate recipient=donor matching included blood type (Table 
1) and body size, with discrepancies in body weight no larger 
than ± 20%, if possible. No prospective tissue typing or 
crossmatching was performed. Before final acceptance of a 
donor heart for transplantation, it was required to have had a 
stable hemodynamic course, a normal or acceptable LV function 
by echocardiogram, and satisfactory contractility by visual 
inspection after opening the chest. Pulmonary artery pressure 
and cardiac output measurements, via Swan Ganz catheter, were 
performed when clinically indicated. Cardiac catheterization 
and angiography were done if donors were older than 45 years 
of age, or if they had a history of hypertension, heavy smoking, 
or prior heart disease. Standard surgical techniques were used 
for organ procurement and graft implantation. All transplanted 
hearts were placed in an orthotopic position. None of the patients 
was mechanically assisted, either pulmonary or cardiac, at the 
time of transplantation. Three patients were hospitalized with 
moderate or severe congestive failure when donors became 
available. Another patient had been hospitalized for more than 
2 months with refractory cardiac failure, requiring 3 weeks of 
intraaortic balloon (IABP) support, and complicated with a 
cerebrovascular accident. She recovered from this episode, was 
discharged home, and transplanted a few weeks later. All donors 
except 1 were from the Honolulu metropolitan area, and they 
were transferred to St. Francis Medical Center to decrease the 
ischemic time. One donor heart was procured in Maui and flown 
to Honolulu for transplantation. 
Results 
Survival/initial hospitalization. Operative mortality was 
5%. Only 1 patient out of 19 died during the immediate postop-
erative period. 
Long-term survival. The 1-year survival rate was 77%, at 3 
years 70% of patients were alive, and 60% survived more than 
5 years. 
Functional results. All surviving patients except 1 became 
asymptomatic following transplantation. The patient who con-
tinued in failure was a very debilitated 60-year-old man who had 
3 previous coronary bypass operations and was hospitalized with 
severe congestive heart failure and anasarca. He also had chronic 
pulmonary disease and following transplantation had a stormy 
course requiring re-exploration for bleeding, prolonged ventila-
tory support, and a tracheostomy. He was discharged after 73 
days in functional class II. Currently more than 2 1/2 years 
following the operation, he still has moderate limitation in 
exercise tolerance. Ten of the 14 patients (71 %) who survived 
more than 1 year were rehabilitated and went back to full- or part-
time work, or full-time school. One patient retired voluntarily. 
-
Cause of death. A total of 6 patients have died: One patient 
died during the initial hospitalization 4 days after the operation; 
5 patients died 4 months to 26 months following transplantation. 
The only hospital death occurred in a 48-year-old woman who 
had early graft failure probably related to pulmonary hyperten-
sion (No. 2, Table 1). 
Of the late deaths, 4 were due to rejection and 1 due to 
infection. The first transplant recipient died 12 months after 
transplantation from complications of rejection that resulted 
from non-compliance with the medical regimen. Severe rejec-
tion was the cause of death in 3 other patients; these occurred 7, 
9, and 22 months following transplantation. The first of these 
patients (No. 13, Table 1) had an uncomplicated operation and 
was discharged after 21 days in the hospital. He subsequently 
had 3 episodes of rejection in the first 3 months, requiring 
intravenous methyl-prednisolone therapy. Seven months after 
the operation, he had an episode of upper respiratory infection 
and presented at another hospital with abdominal fullness and 
dyspnea. Work-up for intra-abdominal pathology delayed the 
diagnosis of rejection, and he presented to St. Francis Medical 
Center in extremis with cardiogenic shock. One gram of methyl-
prednisolone was given at the other hospital before transfer. 
Total cardiopulmonary support (CPS®) was provided, but it 
proved inadequate, with ongoing metabolic acidosis. The same 
day a donor heart became available and the patient was retrans-
planted, but could not be weaned from cardiopulmonary bypass 
and died. The second patient (No. 17, Table 1) had ongoing 
rejection since the transplant operation, and although clinically 
he did well for several weeks at a time, the protracted rejection 
which included alternating or combined humoral and cellular 
rejection, was never fully controlled despite multiple antirejection 
treatments. These included several courses of methyl-
prednisolone, 3 courses of OKT3, 3 courses of plasmapheresis 
or immunoadsorption columns and a full course of total lymph 
node irradiation (80 cGy twice weekly for a total of 10 fractions 
or 800 cGy). He died 9 months after transplantation at home. The 
last of this group of patients (No. 11, Table 1) was admitted 26 
months after transplantation with a severe episode of rejection 
and cardiogenic shock. He was placed on CPS 12 hours after 
admission, but continued deteriorating rapidly despite maximal 
support and died a few hours later. He is the only patient who has 
had documented severe 3-vessel coronary artery disease in the 
transplanted heart. This was known before death on his second-
year routine coronary arteriogram, and confirmed at autopsy. 
The patient who died of infection (No. 7, Table 1) had a 
prolonged re-admission to the hospital with disseminated CMV 
infection and an episode of severe rejection that was reversed 
with the help of CPS for 5 days. The ultimate cause of death was 
multiple organ failure from uncontrollable infection. 
Morbidity 
Infections. Infection episodes were relatively infrequent in 
our patients. Two episodes of successfully treated pneumocystis 
carinii pneumonia occurred in a patient 3 months and 11 months 
after transplant. One patient had disseminated CMV infection 
(previously discussed). Two other patients had systemic symp-
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toms with elevated CMV titers and were treated with intrave-
nous ganciclovir. Bacterial infections were seen infrequently 
and were never of life-threatening proportions. One episode of 
each of the following infections occurred at different occasions: 
Bacterial pneumonia, urinary tract infection, wound infection in 
a traumatic injury, and oral herpes. All of these episodes were 
adequately treated with the appropriate antibiotics. 
Rejection. Of the 18 patients surviving the initial hospitaliza-
tion, 13 patients (72%) suffered at least 1 episode of moderate 
acute cellular rejection requiring treatment during the first year. 
Of the remaining 5 patients, 2 rejected after 1 year, and 3 have 
never had episodes of rejection requiring therapy. As mentioned 
above, 3 patients had severe rejection that led to death, 2 within 
the frrst year, and 1 after 2 years. Humoral (vascular) rejection 
occurred in 3 patients at 2 weeks, 2 months, and 3 years 
following transplantation. These episodes were invariably se-
vere and life-threatening with varying degrees of hemodynamic 
compromise. All 3 patients required admission to ICU and 
inotropic support, and 2 required IABP assistance. Treatment 
included high-dose methyl-prednisolone for 3 days and 
plasmapheresis and/or immunoadsorption columns. The initial 
episodes were reversed in all patients. One patient had recurrent 
rejection and eventually died of it (No. 17, Table 1. Discussed 
above). In the latest patient with humoral rejection, azathioprine 
was substituted with cyclophosphamide with good results. Graft 
atherosclerosis has been diagnosed by coronary angiography in 
1 patient (2 years after transplantation) and confirmed as diffuse, 
severe 3-vessel involvement by autopsy after dying of rejection 
(See above). Another patient suffered an acute myocardial 
infarction several years after transplantation; there were EKG 
changes, but coronary angiography failed to reveal any obstruc-
tive lesions. Bradyarrhythmias occurred in 2 patients whore-
sponded adequately to oral theophylline. None of our patients 
has required implantation of a permanent pacemaker and none 
has developed malignant disease following transplantation. 
Hospital cost 
Information was available on the cost of the initial hospital-
ization of the last 9 transplant patients, all performed within the 
past 3 years. Excluding 2 patients, one with advanced debilita-
tion who spent 2 1/2 months in the hospital following transplan-
tation, and another patient who was hospitalized for 2 months 
before transplantation, the average hospital cost was $157,289. 
This reflects the expected current hospital cost for a relatively 
uncomplicated heart transplant operation excluding physician 
charges. 
Discussion 
Cardiac transplantation has achieved an important position in 
the therapy of incurable cardiac disease. Results have been 
consistently good since the advent of improved immunosup-
pressive methods. With the introduction of cyclosporine in 
1980, the survival rates improved substantially from 63% to 
80% at 1 year, and from 36% to 60% at 5 years. 2 The number of 
transplant centers and operations have increased remarkably in 
the past decade and the number of cardiac transplant operations 
-
worldwide increased from 700 in 1984 to 2, 709 in 1992. A peak 
was reached in 1990 with a total of 3,289 operations. 3 Although 
the considerable increase in the number of operations is encour-
aging, the number of transplant operations remains limited by 
the availability of donors. Nearly 3,000 patients are waiting for 
donor hearts at any given -time in the United States alone. 
Xenotransplantation will have to wait until greater advances in 
immunology take place, and it probably won't be a clinical 
reality within the next decade. 
Selection criteria for recipients continue to evolve, however, 
the initial guidelines set by the Stanford group have remained 
mostly unchanged: The age limit is 60 years old, individualized 
consideration can be given to older patients if they are otherwise 
deemed good candidates. The oldest transplanted patient en-
tered in the Registry of the International Society of Heart and 
Lung Transplantation was 7 5 years old3 -newborns have been 
transplanted hours after birth. All candidates must have end-
stage cardiac disease untreatable by other means with life 
expectancy measured in months, and a normal pulmonary vas-
cular resistance (ideally< 3 Wood units). They should have 
normal or minimally affected kidney and liver function and have 
strong family support and good compliance, since the medica-
tion regimen, and infection and rejection surveillance are very 
stringent. Contraindications include any active infection, peptic 
ulcer disease, recent pulmonary embolism, current malignancy, 
insulin dependent diabetes mellitus and positive serology. 
Operative mortality rates have remained steady at 8% to 
10%3• We had a 5% mortality rate (1/19) and none of the last 17 
patients has died during the initial hospitalization. Long-term 
survival rates are usually reported at yearly intervals with 1-, 5-, 
and 10-year survival rates used to compare results. Stanford 
reports an 80.7% and 59.7% 1- and 5-year survival rates for 
patients treated in the cyclosporine era (1980 to 1989)2• The 
same statistics are 79.1% and 67.8% reported by the Registry3• 
In the latter report, the 10-year survival rate was 55.8%. The 
survivalratesat 1, 3,and5-yearintervalsof77%, 70%, and60% 
in our program are similar to other reports. 
It is unquestionable that cardiac transplantation has a pro-
found effect in patients who are terminally ill and who would 
otherwise have a very limited life expectancy. Not only can this 
procedure add years to their lives, but, equally important, the 
majority of patients become fully rehabilitated and can enjoy 
productive lives. Seventy percent of our patients were able to go 
back to work or school. Similar functional results are reported 
from other institutions.2 
In any organ transplantation, a narrow margin between infec-
tion and rejection is ever-present. Excessive immunosuppres-
sion will decrease the rejection rates, but it will increase the 
incidence and severity of infections. Deficient immunosuppres-
sion will result in fewer infection episodes, but the incidence of 
rejection will increase. Until better immunosuppressive drugs 
become available, we have to accept these potential complica-
tions and treat them with the best means available. Both infec-
tion and rejection remain the main causes of morbidity and 
mortality in transplant patients. As evidenced in our report, the 
majority of patients had at least one episode of rejection, and 5 
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Table 1 Characteristics of Transplant Recipients 
No. Age Sex Diagnosis Blood Type Previous Surgery Length Outcome 
RecDonor of Stay 
50 M IDCM A 0 23 Died 1 year 
2 38 M IDCM B 0 18 Alive 6 years 4 months 
3 48 F IDCM 0 0 4 Died4days 
4 23 M IDCM A A 35 Alive 5 years 6 months 
5 42 M IDCM A 0 24 Alive 5 years 
6 40 M IDCM 0 0 41 Alive 4 years 6 months 
7 25 M LVA 0 0 Aneur resect 18 Died 4 months 
8 34 M IDCM A 0 21 Alive 3 years 9 months 
9 23 M IDCM A 0 18 Alive 3 years 6 months 
10 56 M CAD A 0 CABG 16 Alive 3 years 3 months 
11 34 M IDCM A A 17 Died 2 years 2 months 
12 60 M CAD 0 0 3CABGs 74 Alive 2 years 8 months 
13 32 M IDCM A 0 21 Died 7 month after retransplantation 
14 56 M IDCM 0 0 19 Alive 1 year 1 0 months 
15 56 F IDCM B 0 18 Alive 1 year 6 months 
16 32 M AR 0 0 AVR 19 Alive 1 year 4 months 
17 31 M IDCM B 0 14 Died 9 months 
18 54 M AR 0 0 AVR 24 Alive 13 months 
19 37 M IDCM AB A 16 Alive 7 months 
IDCM=Idiopathic Dilated Cardiomyopathy, LVA=Left Ventricular Aneurysm, CAD=Coronary Artery Disease, CABG=Coronary Artery Bypass 
Grafting, AR=Aortic Regurgitation, AVR=Aortic Valve Replacement 
of 6 deaths were caused by or associated with rejection episodes. 
Typically, cellular rejection is discovered by routine biopsy in 
patients who are. asymptomatic. Treatment with short-term 
enhanced immunosuppression with high-dose steroids aborts 
the episode and no long-lasting heart damage is seen. Recently, 
more serious rejection events have been seen. These are humorally 
mediated and typically present with sudden congestive failure 
symptoms which rapidly may advance to cardiogenic shock. 
These episodes are clearly life-threatening and a very aggressive 
approach is needed to reverse these events. Three of our patients 
have had such complications. Emergency biopsy has revealed 
little or no cellular infiltrates and may show vasculitis. Severe 
-
cardiac dysfunction is evident by clinical symptoms and signs 
and echocardiogram usually confirms the degree of impairment 
of left ventricular contractility. All3 patients required inotropic 
medications to sustain cardiac function: 2 of the patients re-
quired mechanical assistance with IABP, 1 of them on 2 differ-
ent occasions. The biopsy has not always been helpful, but when 
the combination of clinical findings is seen, immediate treat-
ment is given. We have reversed all such episodes with the 
combination of high dose methyl-prednisolone and treatment 
with plasmapheresis or immunoadsorption columns. The 
immunoadsorption columns are used to remove circulating 
immunoglobulins in a selective manner rather than exchanging 
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Table 2 Donors. Cause of Brain Death 
Head Trauma 
Intracranial Bleeding 
Brain Tumor 
MVA=Motor Vehicle accident 
GSW=Gunshot Wound 
MVA 
GSW 
Fall 
8 
5 
1 
5 
the whole plasma volume as plasmapheresis does. This treat-
ment modality has been used in the recent past, and there are no 
reports with large experiences available. We have shown that it 
is an effective way of treating this devastating complication. In 
one patient, we stopped the azathioprine and substituted it with 
cyclophosphamide which has more specific effect on the anti-
body production limb of the immune response. This change 
seems to have controlled the humoral rejection in a better way. 
A serious problem in long-term survivors is the appearance of 
graft coronary atherosclerosis. Stanford reports a 25% incidence 
at 5 years,2 and it seems to correlate with CMV infections. 
Currently, there is no effective way of preventing this complica-
tion. The only effective treatment once it is advanced is 
retransplantation. Fortunately, we have not seen this problem 
frequently in our patients. Only one patient has had significant 
coronary artery obstruction which had no clinical manifesta-
tions. 
Infectious complications have not been a major problem in 
our patient population. It is well known that opportunistic 
infections, mostly fungal and viral, are prevalent in transplanted 
patients. With one exception, all infectious episodes have been 
adequately treated. 
Cardiac transplantation is an expensive procedure. Nonethe-
less, studies have shown this operation to be cost-effective. It is 
clear that most patients with end-stage cardiac disease are 
disabled, many of them being unable to work with resultant loss 
of income, and others have repeated or prolonged hospitaliza-
tions with accumulating health care costs. A transplant opera-
tion often reverses this downhill trend and can return the patient 
to a functional status. The results are not optimal yet and further 
improvements are expected as more experience accumulates, 
but great advances have been made in the past 3 decades. This 
endeavor requires a monumental effort from different institu-
tions and many individuals. The main reward that professionals 
involved in transplantation receive is seeing a patient recover 
from a devastating disease. 
Addendum 
Since the completion of this study, one more patient, our 
longest survivor (who lived more than 6 years) died in January 
1994. The cause of death has not been determined, however his 
death does not alter the 1-year, 3-year or 5-year survival statistics. 
Acknowledgements 
Many individuals have contributed to the care of this group of 
patients, and we are grateful to the following professionals for 
their participation in our transplant program: The operating 
room personnel, intensive care and telemetry nurses at St. 
Francis Medical Center, and other referring hospitals in the state 
of Hawaii. Doctors Livingston Wong, Ricardo Moreno-Cabral, 
Judson McNamara, Mark Grattan, Collin Dang, Leslie Ito, 
Jeffrey Lau, Richard Pang, Robert Hong, Stewart Matsumoto, 
Calvin Wong, Steven Berman, Clifford Chock and John Rausch; 
Mary O'Friel, Sara Ishimoto and Ginger Sawyer of the Organ 
Donor Center of Hawaii; the administration of St. Francis 
Medical Center, and the following services: Pathology, social 
work, dietary, respiratory therapy and physical therapy. Thanks 
to Karen A. Li for her help in preparing the manuscript. 
References 
1. Moreno-Cabral RJ, Wong LMF, McNamara JJ, Matsumoto SY. The first heart 
transplant operation in Hawaii and the prophylactic use of monoclonal antibodies 
(OKT3): a case report. Hawaii Med J. 1988;47:177-181. 
2. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Eight-year results of cyclosporine-
treated patients with cardiac transplants. J Thorac Cardiovas Surg. 1990;99:500-
509. 
3. The Registry of the International Society of Heart and Lung Transplantation: Tenth 
official report-1993. J Heart Lung Transplant. 1993;12:541-548. 
Allogenic and Autologous Bone Marrow Transplant 
Experiences in Hawaii 
~Continued from page 73 
The Hawaii BMT program also has been investigated by 
NMDP. Approval has been given for St. Francis Medical Center 
as one of 72 hospitals capable of performing unrelated alloge-
neic BMT transplants from the world's pool of potential donors. 
Summary 
Allogeneic and autologous bone marrow transplantation has 
been performed in Hawaii since 1978 for leukemia, lymphoma, 
aplastic anemia, and advanced breast cancer. The numbers for 
each group are relatively small and the disease stages are 
diverse. Our program has been recognized and approved by the 
various national organizations, and we hope to continue to 
provide this treatment alternative to appropriate candidates. 
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